Development and Validation of an LC–MS/MS Method for Simultaneous Quantification of Pazopanib, Cabozantinib, Sorafenib, Axitinib, Tivozanib, Sunitinib, and the Metabolites Sorafenib N-Oxide and Desethyl-Sunitinib in Human Plasma

Description

Eva Greibe, Jakob N Henriksen, Niels Fristrup, and Elke Hoffmann-Lücke validate a blood test that measures six cancer drugs at once in a 2026 methods study. The drugs, all tyrosine kinase inhibitors aimed at blood-vessel growth signals, vary wildly in how patients absorb them, and blood levels predict side effects. Their mass spectrometry method also catches two breakdown products, letting clinics adjust doses to the person.

The method read straight-line results across its ranges and passed the standard checks for accuracy, precision, and carry-over. One breakdown product, sorafenib N-oxide, wobbled slightly beyond the precision limit and broke down at room temperature within a day. Everything else stayed stable for a day on the bench and at least five years frozen. Patient samples proved the method works in real care. Greibe's team offers it as a fast, sensitive tool for drug monitoring.

Catalog record

Source: https://europepmc.org/article/MED/PMC13517061